Navigation Links
Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Date:8/22/2007

ROCKVILLE, Md., Aug. 22 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the oral presentation of a paper entitled "Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses" at the AIDS Vaccine 07 conference in Seattle by Dr. Weimin Liu, University of Alabama School of Medicine at Birmingham (UAB). Dr. Liu presented results of pre-clinical immunological studies of improved HIV-1 virus-like particle (VLP) vaccines being developed by scientists at Novavax and leading vaccine experts at UAB, Emory University School of Medicine and Duke University School of Medicine with funding from the National Institutes of Health.

Commenting on the presentation, Dr. Rahul Singhvi, president and CEO of Novavax said, "The data presented today demonstrate that immunization with VLPs containing a consensus envelope protein is a promising approach to achieving the desired broadly neutralizing antibody response against the HIV-1 virus. These data also substantiate the promise of our recombinant VLP technology to design vaccines to ultimately generate an immune response that can prevent complex diseases such as HIV/AIDS."

Virus-like particles (VLPs) represent an attractive HIV-1 vaccine platform for a safe and effective vaccine against HIV/AIDS. VLPs have the potential to mimic the three-dimensional structure of a virus without the risk of replication or infection. Applications of the VLP technology have been limited in the past due to very low level incorporation of HIV-1 envelope glycoprotein, the principal target for neutralizing antibody responses, into the HIV-1 virus or recombinant VLPs. Scientists from Emory University and UAB, working closely with Novav
'/>"/>

SOURCE Novavax, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
2. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
3. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
4. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
5. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
6. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
7. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
8. MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007
9. Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine
10. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
11. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...LIN, Mass., Nov. 26 PLC ... today that it has received full approval from the....S. pivotal trial to study the effectiveness of th...therapy in the prevention of Contrast-Induced Neph...C,s request to expand their investigation from the...
(Date:11/25/2008)...e-FirstCall/ -- Poniard,Pharmaceuticals, Inc. (Na...d on,innovative oncology therapies, announced tod...es for its preclinical research programs in order ...e clinical development of picoplatin,its lead pr...cialization of,picoplatin in the treatment of sma...
(Date:11/24/2008)...o,s Pizza (NYSE: DPZ ), the,recognized world le...gh for,the kids of St. Jude Children,s Research H... campaign. Domino,s customers will have the opport...benefit the children of St. Jude.,Donations can b...ng online at, www.dominos.com . The campaign begi...
(Date:11/24/2008).../ -- Schering-Plough Corporation (NYSE: SGP ) to...tive adenosine2a receptor antagonist, met the prim...atients suffering from moderate to severe Parkinso...normal involuntary movements (dyskinesias). The t... 2008 R&D Update meeting being hosted for anal...
Breaking Medicine Technology:PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 1Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 2Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 3ATV Injuries on the Rise 6905 1ATV Injuries on the Rise 6905 2ATV Injuries on the Rise 6905 3Environmental exodus 1331 1Environmental exodus 1331 2Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers Newark Provost Award 6903 1Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers Newark Provost Award 6903 2
...sults Presented At ASCO -- , CHICAGO – June ... interferon alfa-2b in stage III melanoma had a,si...vival (RFS),according to the results of the large...stage III melanoma. Results of the Phase,III study...h and,Treatment of Cancer (EORTC) and supported by...
...007 - MGI Pharma, Inc.,(Nasdaq:MOGN), a biopharmac..., today provided highlights of data presentations ...Oncology (ASCO) Annual,Meeting. Dacogen (decitabin...ncluding the presentation of efficacy data in olde...nd activity,observed in patients with refractory a...
Other Medicine Technology:Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10
(Date:12/1/2008)...wire-USNewswire/ -- In recognition of World AIDS D...ching a mobile texting campaign to raise money for... a program of the Safe Blood for Africa Foundation...e million lives in Africa by 2011 by working in re...cal training. , , OMALI will be collecting...
(Date:12/1/2008)...RNewswire/ -- TOMS Shoes, the philanthropic,footw...e at TOMSshoes.com,encouraging people to Spend L...s, from November 20th through December 20th, TOMS ...irs of shoes to children in Ethiopia suffering,fr... by wearing shoes. By,purchasing a pair of shoes ...
(Date:12/1/2008)...rom U-M physician include economical options , ...SNewswire/ -- A bottle of cologne, a new pair of p...s to buy and wrap for the upcoming holiday season....y and beneficial to a loved one? Why not give the ... the holidays can be challenging, and this year, m...
(Date:12/1/2008)...swire/ -- TorreyPines Therapeutics, Inc.,(Nasdaq:... of NGX426, an,AMPA/kainate-type glutamate recept...ficant reduction in spontaneous pain, hyperalgesia...(pain resulting from normally non-painful stimuli ...ermal injections of capsaicin in,a human experime...
Breaking Medicine News(10 mins):Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5
...terday about a surgeon Dr Jerome Blanchard who had.../ her with only a diseased one. The disciplinary...hurry removed the wrong kidney from a patient and ...did not bother to read her medical notes. Dr Jerom...
... price tag attached to it.Look at the United State...ealth and opportunity to its people;// but at a co...are 30% Americans who areover-weight or grossly ob...beingmade by China is going to land the country in...
...ude as many patients in the chronic disease manage...ter for Health Khaw Boon Wan who was addressing he...at chronic diseases are major causes of death and ...he past," Khaw said, adding that prompt treatment ...
...everages by the FDA (Food and Drug Administration)...nce of benzene//, a carcinogen in much higher amou...inking water. FDA had alerted these companies, an...te the soft drinks or had already done so. Though ...
Other Medicine News:Health News:Consultant Bungles A Kidney Surgery 2Health News:The Price Paid for New Lifestyle 2Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 2Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 3
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: